KEGG   DRUG: Glucarpidase
Entry
D10260                      Drug                                   

Name
Glucarpidase (INN);
Glucarpidase (genetical recombination) (JAN);
Voraxaze (TN);
Megludase (TN)
Product
Formula
C3670H5926N10114O1140S12
Exact mass
210257.3291
Mol weight
210340.1812
Sequence
MRPSIHRTAI AAVLATAFVA GTALAQKRDN VLFQAATDEQ PAVIKTLEKL VNIETGTGDA
EGIAAAGNFL EAELKNLGFT VTRSKSAGLV VGDNIVGKIK GRGGKNLLLM SHMDTVYLKG
ILAKAPFRVE GDKAYGPGIA DDKGGNAVIL HTLKLLKEYG VRDYGTITVL FNTDEEKGSF
GSRDLIQEEA KLADYVLSFE PTSAGDEKLS LGTSGIAYVQ VNITGKASHA GAAPELGVNA
LVEASDLVLR TMNIDDKAKN LRFNWTIAKA GNVSNIIPAS ATLNADVRYA RNEDFDAAMK
TLEERAQQKK LPEADVKVIV TRGRPAFNAG EGGKKLVDKA VAYYKEAGGT LGVEERTGGG
TDAAYAALSG KPVIESLGLP GFGYHSDKAE YVDISAIPRR LYMARRLIMD LGAGK
  Type
Peptide
Remark
Therapeutic category: 3929
ATC code: V03AF09
Product: D10260<JP/US>
Efficacy
Antidote (methotrexate concentrations)
Comment
Treatment of toxic plasma (methotrexate concentrations)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 V VARIOUS
  V03 ALL OTHER THERAPEUTIC PRODUCTS
   V03A ALL OTHER THERAPEUTIC PRODUCTS
    V03AF Detoxifying agents for antineoplastic treatment
     V03AF09 Glucarpidase
      D10260  Glucarpidase (INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   392  Antidotes
    3929  Others
     D10260  Glucarpidase (INN); Glucarpidase (genetical recombination) (JAN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10260
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10260
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10260
Other DBs
CAS: 9074-87-7
PubChem: 163312291
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system